About Akeso

Kangfang Biology (HKEx: 9926.HK) is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody drugs affordable to patients around the world. Since its inception, the company has successfully established an end-to-end omni-directional drug development platform (ACE platform), covering fully integrated drug discovery and development functions, including target verification, antibody discovery and development, bispecific antibody drug development platform (Tetrabody platform), CMC production process development, large-scale production in line with international GMP standards, and professional commercial operation system. The company currently has more than 30 innovative drug product lines for the treatment of tumor, autoimmune, inflammation, metabolic diseases and other major diseases, of which 15 varieties have entered clinical research, including two internationally pioneered bispecific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). In June 2022, Kang Fang biological world's first tumor double immune checkpoint inhibitor cetanyl (PD-1/CTLA-4 double antibody, caduniril monoclonal antibody injection) in the treatment of cervical cancer was approved and put on the market. Kangfang Bio hopes to become a leading biopharmaceutical company in the world through efficient and breakthrough R & D and innovative development of new drugs that are the first in the world and the best treatment for similar drugs.